Sandler and colleagues validated bevacizumab for lung cancer therapy and showed a clear and meaningful survival advantage with bevacizumab plus chemotherapy vs. chemotherapy alone.39 There are other VEGF specific antibodies under validation, the most important of them is sunitinib, which has shown a great response rate as single agent and appears to be more useful than bevacizumab. This evidence concerns the gene VEGFA and lung cancer.